Main Article Content

Dr Ved Prakash Sharma
Nigar Fatima
Dr Vashishth Mishra
Dr Rajesh Bareja


Increased Prevalence, ESBL, Acinetobacter Species and Double Disc Synergy Test


Introduction: Acinetobacter is an opportunistic pathogen that has evolved into important bacteria associated with nosocomial infections worldwide and is known to develop multidrug resistance (MDR), extensive drug resistance (XDR) and pan drug strains resistance (PDR) including the carbapenem group.

Methods: This study was a hospital cross-sectional study conducted at the Department of Microbiology, Rohilkhand Medical College Bareilly Utter Pradesh on 350 specimens of Acinetobacter species. All clinical specimens of Acinetobacter species were obtained from the microbiology laboratory of Rohilkhand medical college Bareilly. Antimicrobial susceptibility tests (AST) were performed according to the disk diffusion method of scientist Kirby Bauer and based on CLSI guidelines. Extended-spectrum β-lactamase (ESBL)-producing Acinetobacter species were identified using DDST.

Results: Out of 350 samples, 88% of the samples showed resistance to ceftazidime, 78.6% to cefepime and 89.7% to ceftriaxone. Of these, 53% of Acinetobacter isolates were phenotypically found to be ESBL producers.

Conclusion: This current study concluded an alarming level of ESBL producing Acinetobacter spp. in various clinical specimens in the Rohilkhand region. Prevalence of ESBL producing Acinetobacter spp. increasingly threatens health care settings and clinical patient outcomes worldwide and points to the overuse of antibiotics. Detection of an ESBL producer requires active surveillance. This will help prevent the spread of infection.

Abstract 77 | pdf Downloads 37


1. HW Boucher, GH Talbot, JS Bradley, JE Edwards et al. Bad bugs, no drugs: An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1–12.
2. S Saha, KM Devi, S Damrolien, KS Devi. A study of the Acinetobacter infections in a tertiary care hospital in Northeast India. International J Res Med Sci 2018; 6:2076-80.
3. JD Perry. The decade of the development the of Chromogenic Culture Media for Clinical Microbiology in an Era of Molecular Diagnostics. Clin Microbiol Rev. 2017 Apr; 30(2):449-479.
4. N Goel, C Wattal, JK Oberoi, R Raveendran, S Datta, KJ Prasad. The trend analysis of antimicrobial consumption and development of resistance in non-fermenters in a tertiary care hospital in Delhi, India. J Anti microb Che mother. 2011 Jul; 66 (7):1625-30.
5. A Agodi, Zarilli R, Barchitta M et al. Alert surveillance of intensive care unit-acquired the Acinetobacter infections in a Sicilian Hospital. Clin Microbial Infect. 2006; 12: 241-7.
6. S Rungruanghiranya, C Somboonwit, T Kanchanapoom. Acinetobacter infection in the intensive care unit. J Infect Dis Antimicrobial Agents. 2005; 22: 77-9.
7. M Nguyen, SG Joshi. The carbapenem resistance in Acinetobacter baumannii, and their importance in hospital‐acquired infections: a scientific review. Journal of Applied Microbiology. 2021 Dec; 131(6):2715-38.
8. P Gerner-Smidt. Taxonomy and epidemiology of Acinetobacter infections. Rev Med Microbial 1995; 6:186-97.
9. G Mandell, JE Bennett, R Dolin. Principles and practice of infectious diseases. Churchill Livingstone 5th edition 2000; 2:239- 41.
10. KJ Towner. The clinical importance and antibiotic resistance of Acinetobacter spp. J Med Microbiol 1997; 46:721- 46.
11. I Levi, E Rubinstein. Acinetobacter infections-overview of clinical features. In: Bergogne-Berezin I, Jolly Guilloob MI, Towner KJ, editors. Acinetobacter: microbiology, epidemiology, infections, management. Boc a Raton, CRC Press. 1996; 101-15.
12. D Rawat, D Nair. Extended spectrum beta-lactamases in Gram negative bacteria. J Glob Infect Dis. 2010; 2(3):263–274.
13. H Mehrgan, M Rah bar. The prevalence of extended-spectrum beta lactamase-producing Escherichia coli in a tertiary care hospital in Tehran, Iran. Int J Antimicrobial Agents. 2008; 31(2):147–151.
14. I Czobor, I Gheorghe, O Banu et.al. Extended spectrum beta lactums genes in Multi Drug Resistant Gram negative strains isolated in a one year survey from an Intensive Care Unit in Bucharest, Romania. Romanian Biotechnological Letters. 2014; 19(4):9553-60.
15. GG Zhanel, CD Lawson, H Adam et al, Ceftazidime-avibactum: a novel cephalosporin/beta lactamase inhibitor combination. Drug. 2013 73,159-177.
16. RR Teimoor, MB Sunita, SM. Meera Phenotypic characterization of Acinetobacter species and their resistance pattern in a tertiary care hospital IP International j med microbial.2022;8(1):78-82.
17. A Kaur, V Gupta, D Chhina, Prevalence Metellobetalactamase producing Acinetobacter species in a tertiary care hospital. Iran j Microbiol.2014; 6(1):22-5.
18. K Prashanth, S Badrinath. In vitro susceptibility pattern of Acinetobacter species to commonly used cephalosporins, quinolones and amino glycosides. Indian J med Microbiol 2004; 22 (2): 97-103.
19. M Choudhry, A Payasi, Molecular characterization and in vitro susceptibilities of β-lactamase producing Escherichia coli, Klebsiella species, Acinetobacter baumannii, Pseudomonas aeruginosa and Staphylococcus aureus to CSE1034 and other β-lactams. Asian Pac J Trop Med 2014; 7(1): S217-S223.
20. R Reza, T Sajjad, Z Shahin, S Mehrdad. The Frequency of Antibiotic Resistance and Extended spectrum beta lactums among the clinically Acinetobacter baumannii Strains Isolated from the Patients in a Major Hospital in Tehran, Iran. The Open Microbiology Journal.2018; 12: 255.
21. ARamoul,S. hammami, M.Dekhil,S.Aimiri, A.salim, and I. Boutiba-BenBoubaker. Phenotypic and genotypic chrecterization of clinical multidrug resistance Acinetbacter baumanniifrom Algerian intensive care units.African journal of Microbology Research.2013; 868:2013.
22. Faten M Elabd, MohamedS.z. al-ayed, Ahmad M. asaad, Saeed A. Alsareii, Mohamed A.Qureshi,HassanA-A.Musa.Molecular characterization of Oxacillinase resistant Acinetobacter baumannii nosocomial isolates in a Saudi hospital.Journal. of infection and public health2015;242-247.
23. Clinical Laboratory and Standards Institute, Performance standard for antimicrobial susceptibility testing; twenty first informational supplements, Clinical and laboratory standard institute Doc., M100Ed29.2019.
24. Performance standards of Antimicrobial Susceptibility Testing; Twenty Eight Informational Supplement. M100-S28, Vol. 38, No.3, Jan 2018.